Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.22.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Operating expenses:    
Research and development $ 72,071 $ 34,184
Selling, general and administrative 22,272 11,644
Total operating expenses 94,343 45,828
Loss from operations (94,343) (45,828)
Interest and other income, net 788 480
Interest expense (31) (863)
Income from equity method investment 14,458 4,710
Gain from change in fair value of warrants and earnout shares 16,814 0
Total other income, net 32,029 4,327
Loss before income taxes (62,314) (41,501)
Income tax expense 5 4
Net loss $ (62,319) $ (41,505)
Net loss per share, basic and diluted $ (0.11) $ (0.37)
Weighted-average common shares outstanding, basic and diluted 579,090,606 111,012,510